| abstract |
A low-molecular VEGF inhibitor usable in the treatment of diseases accompanied by neovascularization such as solid cancer. A polypeptide containing the first immunoglobulin-like domain and the second immunoglobulin-like domain in the extracellular region of a VEGF receptor FLT but not containing the sixth immunoglobulin-like domain and the seventh immunoglobulin-like domain thereof shows a VEGF inhibitory activity. |